Total Payments
$202,473
2024 Payments
$9,103
Companies
6
Transactions
239
Medicare Patients
5,913
Medicare Billing
$421,220
Payment Breakdown by Category
Consulting$202,275 (99.9%)
Food & Beverage$149.36 (0.1%)
Other$48.54 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $202,275 | 234 | 99.9% |
| Food and Beverage | $149.36 | 4 | 0.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $48.54 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boston Scientific Corporation | $202,275 | 234 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $73.20 | 1 | $0 (2024) |
| Medtronic Vascular, Inc. | $48.54 | 1 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $29.77 | 1 | $0 (2024) |
| Akcea Therapeutics, Inc. | $27.11 | 1 | $0 (2019) |
| Abbott Laboratories | $19.28 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,103 | 18 | Boston Scientific Corporation ($9,000) |
| 2023 | $19,463 | 39 | Boston Scientific Corporation ($19,463) |
| 2022 | $31,275 | 43 | BOSTON SCIENTIFIC CORPORATION ($31,275) |
| 2021 | $50,507 | 40 | BOSTON SCIENTIFIC CORPORATION ($50,488) |
| 2020 | $34,263 | 35 | Boston Scientific Corporation ($34,263) |
| 2019 | $31,277 | 29 | Boston Scientific Corporation ($31,250) |
| 2018 | $15,361 | 22 | Boston Scientific Corporation ($15,313) |
| 2017 | $11,225 | 13 | BOSTON SCIENTIFIC CORPORATION ($11,225) |
All Payment Transactions
239 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: Clinical Trial Product_PI | ||||||
| 10/24/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: Clinical Trial Product_PI | ||||||
| 09/06/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $73.20 | General |
| Category: Genetic Disease | ||||||
| 09/05/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $29.77 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/29/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: Clinical Trial Product_PI | ||||||
| 05/31/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| Category: Clinical Trial Product_PI | ||||||
| 05/31/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $1,012.50 | General |
| Category: Clinical Trial Product_PI | ||||||
| 05/24/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| Category: Clinical Trial Product_PI | ||||||
| 05/24/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Clinical Trial Product_PI | ||||||
| 05/24/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $562.50 | General |
| Category: Clinical Trial Product_PI | ||||||
| 05/24/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: Clinical Trial Product_PI | ||||||
| 05/17/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: Clinical Trial Product_PI | ||||||
| 03/01/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: Clinical Trial Product_PI | ||||||
| 01/26/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Clinical Trial Product_PI | ||||||
| 01/26/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $562.50 | General |
| Category: Clinical Trial Product_PI | ||||||
| 01/26/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $562.50 | General |
| Category: Clinical Trial Product_PI | ||||||
| 01/26/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: Clinical Trial Product_PI | ||||||
| 01/12/2024 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: Clinical Trial Product_PI | ||||||
| 12/29/2023 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| Category: Clinical Trial Product_PI | ||||||
| 12/22/2023 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: Clinical Trial Product_PI | ||||||
| 12/22/2023 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: Clinical Trial Product_PI | ||||||
| 12/15/2023 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: Clinical Trial Product_PI | ||||||
| 12/15/2023 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: Clinical Trial Product_PI | ||||||
| 10/13/2023 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: Clinical Trial Product_PI | ||||||
| 10/13/2023 | Boston Scientific Corporation | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Clinical Trial Product_PI | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 1,644 | 1,847 | $554,383 | $109,336 |
| 2022 | 25 | 1,493 | 1,625 | $478,320 | $100,697 |
| 2021 | 26 | 1,494 | 1,620 | $481,506 | $115,255 |
| 2020 | 21 | 1,282 | 1,413 | $420,721 | $95,932 |
Total Patients
5,913
Total Services
6,505
Medicare Billing
$421,220
Procedure Codes
125
All Medicare Procedures & Services
125 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 233 | 272 | $107,277 | $23,027 | 21.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 156 | 156 | $117,498 | $22,408 | 19.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 236 | 237 | $63,208 | $11,737 | 18.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 81 | 151 | $47,369 | $8,833 | 18.6% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 21 | 22 | $34,971 | $6,526 | 18.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 53 | 53 | $31,556 | $5,219 | 16.5% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 21 | 41 | $15,715 | $3,786 | 24.1% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 18 | 72 | $10,966 | $3,326 | 30.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 24 | 24 | $12,367 | $2,808 | 22.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 16 | 16 | $13,962 | $2,122 | 15.2% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 12 | 12 | $10,498 | $2,073 | 19.7% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 26 | 26 | $7,558 | $1,466 | 19.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 14 | $6,310 | $1,290 | 20.4% |
| 78431 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | Facility | 2023 | 20 | 20 | $6,720 | $1,244 | 18.5% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 55 | 57 | $5,216 | $1,107 | 21.2% |
| 93308 | Ultrasound of heart, follow-up | Office | 2023 | 14 | 14 | $5,159 | $1,056 | 20.5% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 21 | 21 | $5,403 | $1,023 | 18.9% |
| 93350 | Ultrasound of heart during rest, exercise and/or drug-induced stress with report | Facility | 2023 | 19 | 19 | $4,834 | $1,020 | 21.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 88 | 96 | $5,938 | $1,007 | 17.0% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 11 | 11 | $4,329 | $913.77 | 21.1% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Facility | 2023 | 45 | 45 | $4,397 | $890.56 | 20.3% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Facility | 2023 | 46 | 47 | $4,183 | $824.85 | 19.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 11 | 11 | $3,806 | $793.21 | 20.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 11 | 11 | $4,338 | $665.82 | 15.3% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 40 | 40 | $3,236 | $614.57 | 19.0% |
About Dr. David Hurrell, MD
Dr. David Hurrell, MD is a Cardiovascular Disease healthcare provider based in Minneapolis, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1194784835.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Hurrell, MD has received a total of $202,473 in payments from pharmaceutical and medical device companies, with $9,103 received in 2024. These payments were reported across 239 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($202,275).
As a Medicare-enrolled provider, Hurrell has provided services to 5,913 Medicare beneficiaries, totaling 6,505 services with total Medicare billing of $421,220. Data is available for 4 years (2020–2023), covering 125 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Minneapolis, MN
- Active Since 03/21/2006
- Last Updated 03/11/2021
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1194784835
Products in Payments
- CLINICAL TRIAL PRODUCT (Device) $155,238
- ELUVIA (Device) $6,550
- Clinical Trial Product (Device) $6,138
- GENERAL STENTS (Device) $2,513
- INNOVA (Device) $1,425
- GENERAL - THERAPIES (Device) $1,050
- GENERAL STENTS (Device) $900.00
- AMVUTTRA (Drug) $73.20
- WAINUA (Drug) $29.77
- TEGSEDI (Drug) $27.11
- HeartMate 3 Left Ventricular Assist Device (Device) $19.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Minneapolis
Dr. Jeffrey Chambers, M.d, M.D
Cardiovascular Disease — Payments: $3.1M
Cardiovascular Disease $3.1M
Dr. Markus Meyer, M.d, M.D
Cardiovascular Disease — Payments: $716,757
Cardiovascular Disease $716,757
Robert Schwartz, Md, MD
Cardiovascular Disease — Payments: $627,332
Cardiovascular Disease $627,332
Emmanouil Brilakis, Md, MD
Cardiovascular Disease — Payments: $625,583
Cardiovascular Disease $625,583
Robert Van Tassel, Md, MD
Cardiovascular Disease — Payments: $592,604
Cardiovascular Disease $592,604
Dr. Inderjit Anand, Md, Frcp, D Phil, Fa, MD, FRCP, D PHIL, FA
Cardiovascular Disease — Payments: $497,056
Cardiovascular Disease $497,056